Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05721573 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
A Phase 2 study, sponsored by Abcuro.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT05721573: Completed Phase 2 study, sponsored by Abcuro.
NCT05721573 is a Phase 2 study that has completed, run by Abcuro. The registered enrollment target is 272 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05721573, a Phase 2 study, has completed, sponsored by Abcuro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
Primary Outcome
Safety as assessed by the incidence, type and severity of Treatment Emergent Adverse Events (TEAEs)
Interventions
- DRUG ABC008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-11-27 |
| Phase | Phase 2 |
What the finished NCT05721573 record still lists
NCT05721573 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 1 intervention - of which ABC008 is the first listed.
NCT05721573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05721573 about?
NCT05721573 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis". A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
What is the current status of trial NCT05721573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2023-02-28. Estimated completion is 2025-11-27.
What interventions are being tested in trial NCT05721573?
The interventions under investigation include: ABC008 (DRUG).
Who is sponsoring clinical trial NCT05721573?
This trial is sponsored by Abcuro, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05721573's enrollment target sits among peer trials
272 204th of 2000 higher than 1,796 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI